SET pseudogene 8 (SETP8)

SET pseudogene 8 is catalogued as a pseudogene and not a functional gene product[1][3]. Pseudogenes are typically non-functional remnants of genes that have acquired disabling mutations and do not encode active proteins, enzymes, or receptors. Although emerging research suggests that some pseudogenes may play regulatory roles, such as influencing gene expression or RNA stability, there is no evidence that SET pseudogene 8 performs any such function, nor is it associated with disease or pharmacological intervention in any species[1][3][7]. As such, it is not a therapeutic target and is not appropriated for drug discovery contexts. Important clarification: This entry seems to be an error or misunderstanding, as pseudogenes like SET pseudogene 8 are not typically considered molecular targets in drug discovery or therapy. It is not a canonical receptor, enzyme, transporter, or other pharmacologically relevant protein. No established abbreviation beyond SETP8 is in use, and it does not appear in drug-target interaction databases. If the intent was to reference a functional gene such as "SET domain containing lysine methyltransferase 8" (also abbreviated as SET8 or KMT5A), that would be a distinct entity—a bona fide methyltransferase enzyme with known biological and pathological roles. However, this is not SETP8 or SET pseudogene 8. If a functional target was intended (like "SET domain containing lysine methyltransferase 8"), please clarify, as this pseudogene is not a therapeutic target in its own right[1][3][7].